GRI Bio reports Q1 net loss $3.0M; GRI-0621 Phase 2a IPF trial on track for data in Q2/Q3 2025

GRI Bio, Inc.

2025-Q1 EPS reported -$5.80

Net loss of $3.0M for Q1 2025; R&D expenses $1.6M, G&A $1.4M.
Cash $3.3M at March 31; subsequent $5M public offering; cash runway expected through Q3 2025.
Phase 2a trial of GRI-0621: 6-week interim data (n=24) expected Q2 2025; topline data Q3 2025.
Interim 2-week data in first 12 patients showed safety, no hyperlipidemia, and biomarker PRO-C3 suggestive of anti-fibrotic effect.
Enrollment over two-thirds complete for overall Phase 2a IPF trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.